Abu Dhabi successfully accomplishes the first clinical trial to treat osteoporosis in the knee

The Department of Health – Abu Dhabi, the organizational authority for the health care sector in the emirate, has revealed the completion of a pioneering clinical trial in Abu Dhabi in cooperation with the Swedish Biotechnology Company “Silclaps” and Barjeel Holding, which has proven the efficiency of Stromaforte, a medical cell product. The product, developed by “Silclaps”, showed a suitable safety file and great treatment capabilities for osteoporosis in the knee, which represents an important achievement in assessing options for treating degenerative joint diseases using cells.

The study holds the regenerative properties of medium stem cells, a type of stem cell known for their ability to reduce infections, repair and regenerate damaged tissues. These cells are naturally found in the body, and they act as a biological medium by discovering the places of deterioration or injury and alerting the body to launch the self -hospitalization process, instead of just replacing damaged cells.

Medium stem cells were directly injected into the affected joints in patients, knowing that these cells were carefully extracted from healthy donors whose safety was accurately verified, and they are between the ages of 18 and 30 years. The aim of this was to verify the safety of the procedure and its ability to reduce pain and infections and the ability to repair cartilage damage to provide a possible alternative to the surgical option that people with osteoporosis benefit from the knee. The experiment was conducted under the leadership of Dr. Osama Al -Shaar, a consultant orthopedic surgery and Dr. Ferrabahu Metosami, orthopedic specialist, and was conducted in Burjeel Medical City and Burjeel Hospital between November 2023 and October 2024, during which patients obtained an ultrasound injection. The results of the first stage of the experiment (the stage LL/L) were encouraging, as it managed to achieve the main goal specified at the level of treatment of treatment, which was confirmed by an independent committee to monitor safety.

Patients reported a noticeable decrease in pain levels, as it was measured using visual analog scale, as well as a comprehensive improvement in the quality of their lives, enabling them to move with more comfort and easily practicing their daily activities. And most importantly, their response to treatment was good without recording any severe side effects.

To further assess the efficiency of treatment, and obtain more accurate information about its effect, patients were examined using magnetic resonance. The results are scheduled to be presented in detail during the Abu Dhabi International Health Week next April.
The Executive Director of the Health Life Sciences Sector in the Health Department – Abu Dhabi, Dr. Asma Ibrahim Al -Mannai, stressed the importance of this achievement, saying: “Our success in conducting this clinical experiment provides evidence of the growing capabilities of the Emirate of Abu Dhabi in conducting global medical research and developing the first treatment options. The profession, by focusing on cell therapy, genetic and regenerative treatment, priority, we pave the way for promising treatments that improve the quality of patients ’life and their therapeutic results, while all these efforts come to consolidate the position of Abu Dhabi as a pioneering center for health care and life sciences, and continue to formulate the future of medicine and upgrade the levels of patient care.”

This clinical experience was conducted in cooperation with the international experts of “Silclaps”, which is one of the members of the global technology system in Abu Dhabi “HAB 71”, where it worked closely with the Health Department – Abu Dhabi and Burjal Medical City to provide this advanced treatment using stem cells to patients in the UAE.

“This clinical experience is a remarkable achievement within the efforts of Abu Dhabi to consolidate its global leading position in renewal medicine. We are proud of the” Silclaps “company by harnessing our expertise in stem cells to provide these innovative treatment and based on scientific evidence for patients who suffer from osteoporosis in the knee. By combining the commitment of the Health Department – Abu Dhabi to innovation in health care, our advanced techniques and our extensive experience in the field of stem cells, we can provide safer and efficient non -surgical treatment options and able to enhance the quality of the lives of thousands of patients who suffer from osteoporosis in the UAE.

“The exceptional success of the Stromaforte experience on the growth of the biotechnology sector in Abu Dhabi. With the continued research and development, it is possible for stem cell therapy to rise with osteoporosis and give patients a non -surgical option to relieve their pain and improve their ability to move.”